United States
Content provided by Bausch + Lomb Medical Affairs.
Content provided by Bausch + Lomb Medical Affairs.
Delving into hot topics for anterior segment surgeons and eye care professionals, focused on advancing eye care across cataract and refractive practice. Bausch + Lomb participated with 7 confirmed abstract acceptances, including 4 oral presentations. Communications highlighted data across cataract and refractive surgery with the enVista® family (enVista Envy™, enVista Aspire™), and vitreoretinal surgical performance (Stellaris Elite®).
PURPOSE: Lifitegrast ophthalmic solution 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). This survey of eyecare providers aimed to examine real-world utilization and outcomes of lifitegrast in the treatment of patients with DED.
METHOD: Eyecare providers (ECPs: ophthalmologists and optometrists) treating patients with DED were invited to complete a provider survey. The survey included items regarding practice characteristics, lifitegrast utilization, satisfaction, and adverse events (AEs). Satisfaction with lifitegrast relative to other prescription eye drops was rated on a scale from 0 (very dissatisfied) to 10 (very satisfied). ECPs also provided case study data for up to five patients with DED who initiated lifitegrast treatment.
RESULTS: 12 ECPs treated an average of 1288 patients with DED annually, with 21% of these patients, on average, receiving lifitegrast. Nearly all ECPs (92%) reported treating contact lens–induced DED with lifitegrast. Other predominant uses of lifitegrast included prior to or after refractive or cataract surgery (83% each). Two-thirds (67%) of ECPs reported near/complete symptom resolution in patients after 1-3 months of lifitegrast treatment. Satisfaction ratings (mean [range]) for onset and effectiveness were 6.8 (3-9) and 6.6 (3-9), respectively. 7 ECPs provided 36 case reports of patients (mean age, 51 years; mean number of follow-up visits, 5) with aqueous deficient (39%), evaporative (14%), or mixed (47%) DED. Case report data indicated that improvement was sustained throughout treatment, with a mean duration of 29 months (range, 1-69). 58% of ECPs reported that at least 1 patient experienced an AE during lifitegrast treatment; all AEs were mild or moderate in severity. AEs considered by the ECPs as related to lifitegrast use included blurred vision, burning/stinging, and dysgeusia.
CONCLUSION: Findings from this real-world survey of ECPs highlight the rapid and durable response associated with lifitegrast for the treatment of patients with DED. AEs were consistent with the known safety profile of lifitegrast.
PURPOSE: To evaluate visual acuity and patient-reported outcomes following IOL exchange surgery with a full visual range (FVR) IOL.
METHODS: Case records of 12 patients (16 eyes) who were dissatisfied with previously implanted Clearview 3, Tecnis Odyssey, Alcon PanOptix or monofocal IOLs and underwent IOL exchange with the enVista Envy FVR IOL were retrospectively reviewed. Outcome measures were visual acuity and subjective patient experience following the exchange.
RESULTS: Following IOL exchange with the FVR IOL, mean logMAR UDVA was 0.09±0.16, with 81.3% of eyes achieving 20/25 or better. Mean logMAR UNVA was -0.08±0.04, and all (100%) eyes achieved 20/25 or better. Mean MRSE was -0.20±0.32 D. Patients exchanged from ClearView 3 to Envy reported resolution of starbursts, glare and hazy vision. Patients exchanged from Odyssey witnessed fewer halos, improved peripheral vision and better contrast. One PanOptix IOL-implanted eye that experienced constant halos also reported improvement in subjective vision following exchange. All patients reported good satisfaction.
CONCLUSION: IOL exchange to enVista Envy FVR IOL yielded good outcomes at distance and near. Visual disturbances such as peripheral vision blur, starbursts, hazy vision, glare, and halos reported with previously implanted IOLs resolved after exchange. Patients were satisfied with the Envy IOL compared to previously explanted IOL.
PURPOSE: To assess visual outcomes at different distances, refraction and safety profile of the enVista ENVY full visual range intraocular lens following cataract surgery.
METHODS: A single U.S. surgeon implanted the enVista ENVY (EN) and the enVista ENVY toric (ETN) IOLs in 49 patients (71 eyes) between November 6, 2024, and July 30, 2025. This case series assesses postoperative performance at distance, intermediate and near vision, mean refractive spherical equivalent (MRSE), and occurrence of glistenings, posterior capsule opacification (PCO), and adverse events (AEs).
RESULTS: 28 eyes were implanted with EN and 43 eyes with ETN, with a mean±SD target SE of –0.23±0.16 (n=27) and –0.19±0.13, respectively. Monocular CDVA ≤20/25 was achieved in 100% (EN) and 95% (ETN); UDVA ≤20/32 in 86% and 77%; UIVA ≤20/25 in 95% and 84%; and UNVA ≤ J2 in 79% and 76%, respectively. Binocular CDVA ≤20/25 was achieved in 100% (EN) and 92% (ETN). Mean±SD MRSE and residual cylinder were –0.06±0.40 and –0.36±0.28 (EN), and –0.32±0.32 and –0.40±0.35 (ETN). No serious AEs or glistenings were observed.
CONCLUSION: enVista ENVY provided excellent refractive accuracy and a high visual performance at distance, intermediate and near, with no serious AEs or glistenings reported.
This research evaluates the visual acuity outcomes and defocus curve following bilateral implantation of an enhanced monofocal IOL in cataract patients. The ambispective, single-arm study included 82 subjects who had undergone bilateral implantation of an enhanced monofocal IOL (enVista ASPIRE, Bausch and Lomb). Outcome measures assessed at least 2 months after IOL implantation in the second eye included monocular (first-implanted eye) and binocular visual acuities, as well as the binocular defocus curve. Postoperatively, mean monocular logMAR UDVA was 0.12±0.14 and CDVA was −0.01±0.09. Mean MRSE was −0.38±0.47 D. Mean monocular logMAR UIVA and UNVA were 0.2±0.15 and 0.42±0.17, with 58.5% and 34.1% of eyes achieving UIVA 20/32 or better, and UNVA 20/40 or better, postoperatively. Mean binocular logMAR DCIVA and DCNVA were 0.21±0.13 and 0.39±0.14, respectively, with 65.9% of patients achieving DCIVA 20/32 or better, and 35.4% achieving DCNVA 20/40 or better. Defocus curve showed 20/32 or better visual acuity for a defocus range of ~ +1.00 D to −1.25 D. In conclusion, implantation of an enhanced monofocal IOL increased the depth of focus, providing a mean uncorrected visual acuity of 20/26 at distance and 20/32 at intermediate.
Assessment: The enVista ENVY (EN) intraocular lens (IOL) provides up to 4 D of continuous visual range with enhanced tolerance to dysphotopsia. This retrospective case series documents healthcare providers' real-world experience of using the EN IOL, including satisfaction, IOL utilization patterns, and patient outcomes.
METHODS: This sub-analysis of a multicentre, cross-sectional retrospective case series documents real-world outcomes following implantation with the enVista ENVY (EN) full visual range intraocular lens (IOL). Thirteen HCPs in the USA (n=12) and Canada (n=1) provided a convenience sample of EN electronic medical record cases using a standardized case report form to document real-world clinical performance. Procedures were conducted between 14 October 2024 and 30 July 2025. Key outcome measures included corrected and uncorrected distance and uncorrected intermediate and near visual acuity (CDVA, UDVA, UIVA, UNVA), refractive outcomes, and adverse events (AEs).
RESULTS: The analysis included 94 patients (144 eyes); 44 unilateral, 50 bilateral. The mean±SD spherical equivalent target was 0.05±1.91 (n=135). Following surgery, a monocular CDVA of ≤20/25 was achieved in 98% of eyes (116/118); UDVA of ≤20/32 in 88% of eyes (117/133), UIVA of ≤20/32 in 91% of eyes (53/58); UNVA of ≤J2 in 78% of eyes (88/113). Binocular CDVA of ≤20/25 was achieved in 100% of patients (42/42). Mean±SD MRSE was −0.09±0.38 (n=116). No serious AEs were reported. No patients reported glistening.
CONCLUSION: In this multicenter, cross-sectional, retrospective study, the EN IOL provided excellent distance, intermediate, and near visual acuity for most patients, with no glistening or serious AEs reported.
PURPOSE: Dry eye disease (DED) is common in patients undergoing cataract surgery. Perfluorohexyloctane ophthalmic solution (PFHO) forms an anti-evaporative monolayer at the tear-film surface to reduce both signs and symptoms of DED. This study evaluated the use of PFHO in patients undergoing cataract surgery.
METHODS: This prospective, multicenter, open-label, phase 4 study (NCT06346340) enrolled patients with DED who were candidates for phacoemulsification with posterior chamber intraocular lens (IOL) implantation. Patients instilled PFHO in both eyes QID for 30 days preoperatively and received a second 30-day PFHO treatment beginning approximately 1 month after surgery.
RESULTS: The study enrolled 97 patients (75.3% female; mean age, 68.6 years). The mean difference in absolute deviations between manifest refraction and predicted refractive error measured before and after preoperative PFHO treatment (primary endpoint) was -0.027 ± 0.167 D (P=0.1385). The difference in predicted refractive error at baseline versus post-PFHO treatment was within ±0.3 D for 94.2% of study eyes. The percentage of patients with calculated IOL power within ±0.50 D of the correct IOL power was 72.1% before and 83.7% after PFHO treatment. Treatment with PFHO significantly improved DED signs and symptoms, including total and central corneal fluorescein staining, eye dryness, and Ocular Surface Disease Index scores, before and after cataract surgery (P<0.0001 for all. most patients experienced stable or improved root mean square higher-order aberrations in the central 6.0 mm of the cornea after pfho treatment. the percentage of patients with best-corrected visual acuity of 20 20 or better was 86.0 at first postoperative assessment and 91.8 after 30 days of subsequent pfho treatment. two adverse events were considered related to treatment mild eye pruritus and mild noninfective conjunctivitis.>
CONCLUSION: In patients with DED undergoing cataract surgery, PFHO did not alter the accuracy of preoperative biometry and keratometry measurements or impact the predicted refractive error. Patients experienced significant reductions in signs and symptoms of DED. PFHO was well tolerated in this patient population.
ASSESSMENT: Inflow outflow compensation factors may benefit IOP stability when performing vitrectomy. Our goal is to demonstrate that increased usability is achievable without sacrificing vitrectomy efficiency.
METHODS: Tests were performed with the Stellaris Elite vision enhancement system and the BL-PAF Bi-Blade® dual-action vitrectomy probes. Infusion pressure, vitrectomy time and aspiration volume were measured. Statistical significance was calculated using a two-tailed t-test with α = 0.05.
RESULTS: There was statistically significant improvement when comparing the PAF system to the conventional intraocular pressure control system at all tested cut rate levels: at the maximum cut rate, IOP was 21.4 mmHg with PAF compared to 17.1 mmHg with the conventional system. The average flow rate using BL-PAF was 1.84±0.05 ml/min, comparable to the average flow rate of the conventional system (1.85±0.05 ml/min) (cut rate = 15,000 cuts/min, vacuum = 650 mmHg, p>0.4).
CONCLUSION: In conclusion, the PAF and 25g dual-action cutters increase usability of the Stellaris Elite vision enhancement system by providing tighter IOP control during vitrectomy with no statistically significant trade-off in flow rate or vitrectomy time.
Get Support
Contact UsContact a
Representative
Submit a
Medical Inquiry
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.
